Literature DB >> 8952537

Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders.

Y Inoue1, T E King, S S Tinkle, K Dockstader, L S Newman.   

Abstract

Mast cells (MCs) are abundant in fibrotic tissue, although their role in fibrogenesis remains obscure. Recent studies suggest MCs may produce basic fibroblast growth factor (bFGF). To evaluate the hypothesis that MC bFGF contributes to the fibrotic response in human interstitial lung disease, we studied lung tissue, bronchoalveolar lavage fluid and serum in 1) idiopathic pulmonary fibrosis, 2) chronic beryllium disease and sarcoidosis, 3) control subjects with no disease or who were beryllium sensitized with normal lung histology. Diseased subjects underwent clinical assessments to stage disease severity. We determined that most bFGF+ cells in lung interstitium are MCs and are most abundant in idiopathic pulmonary fibrosis. Distribution of bFGF+ MCs matched that of extracellular matrix deposition and correlated with the extent of fibrosis morphometrically. Only one bFGF isoform (17.8 kd) was found in idiopathic pulmonary fibrosis and chronic beryllium disease lung tissues and interacted with heparin-like molecules in the lung. Using a human MC line, we verified that MCs express bFGF mRNA and protein that localizes to cytoplasmic granules. Clinically, bFGF concentrations in bronchoalveolar lavage fluid and serum were highest in disease states and correlated with bronchoalveolar lavage cellularity and severity of gas exchange abnormalities, supporting a role for MC bFGF in the pulmonary fibrotic response and its clinical consequence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8952537      PMCID: PMC1865345     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  67 in total

Review 1.  Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins.

Authors:  P M Henson; R B Johnston
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

2.  Mast cells and fibrosis--who's on first?

Authors:  M Jordana
Journal:  Am J Respir Cell Mol Biol       Date:  1993-01       Impact factor: 6.914

Review 3.  Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis.

Authors:  I Vlodavsky; Z Fuks; R Ishai-Michaeli; P Bashkin; E Levi; G Korner; R Bar-Shavit; M Klagsbrun
Journal:  J Cell Biochem       Date:  1991-02       Impact factor: 4.429

4.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

5.  Macrophage production of basic fibroblast growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury.

Authors:  C Henke; W Marineili; J Jessurun; J Fox; D Harms; M Peterson; L Chiang; P Doran
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

6.  Heparin stimulates the proliferation of bovine aortic endothelial cells probably through activation of endogenous basic fibroblast growth factor.

Authors:  S Tazawa; Y Hayakawa; T Ishikawa; K Niiya; N Sakuragawa
Journal:  Thromb Res       Date:  1993-12-01       Impact factor: 3.944

7.  Basic fibroblast growth factor in Dupuytren's contracture.

Authors:  A M Gonzalez; M Buscaglia; R Fox; A Isacchi; P Sarmientos; J Farris; M Ong; D Martineau; D A Lappi; A Baird
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

8.  Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin.

Authors:  J R Gordon; S J Galli
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

9.  Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis?

Authors:  R A Hawkins; H N Claman; R A Clark; J C Steigerwald
Journal:  Ann Intern Med       Date:  1985-02       Impact factor: 25.391

Review 10.  Recent developments in the cell biology of basic fibroblast growth factor.

Authors:  D B Rifkin; D Moscatelli
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  29 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin.

Authors:  Robert D Guzy; Ivan Stoilov; Timothy J Elton; Robert P Mecham; David M Ornitz
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

Review 3.  The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not.

Authors:  Yael Aschner; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

4.  Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis.

Authors:  Seung-Ick Cha; Christine S Chang; Eun Kyung Kim; Jae W Lee; Michael A Matthay; Jeffrey A Golden; Brett M Elicker; Kirk Jones; Harold R Collard; Paul J Wolters
Journal:  Histopathology       Date:  2012-03-06       Impact factor: 5.087

5.  Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients.

Authors:  Sangita P Patil; Juan P Wisnivesky; Paula J Busse; Ethan A Halm; Xiu-Min Li
Journal:  Ann Allergy Asthma Immunol       Date:  2011-01-14       Impact factor: 6.347

6.  Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation.

Authors:  Hyun Young Koo; Lamis Mf El-Baz; StaceyL House; Sarah N Cilvik; Samuel J Dorry; Nahla M Shoukry; Mohamed L Salem; Hani S Hafez; Nickolai O Dulin; David M Ornitz; Robert D Guzy
Journal:  J Pathol       Date:  2018-07-05       Impact factor: 7.996

7.  Are mast cells implicated in asphyxia?

Authors:  Barbara Muciaccia; Cristina Sestili; Stefania De Grossi; Annarita Vestri; Luigi Cipolloni; Rossana Cecchi
Journal:  Int J Legal Med       Date:  2015-06-11       Impact factor: 2.686

Review 8.  Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases.

Authors:  Katy M Roach; Peter Bradding
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

9.  Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor.

Authors:  S Mark Duffy; Glenn Cruse; Christopher E Brightling; Peter Bradding
Journal:  Eur J Immunol       Date:  2007-06       Impact factor: 5.532

10.  Engagement of the EP2 prostanoid receptor closes the K+ channel KCa3.1 in human lung mast cells and attenuates their migration.

Authors:  S Mark Duffy; Glenn Cruse; Sarah L Cockerill; Chris E Brightling; Peter Bradding
Journal:  Eur J Immunol       Date:  2008-09       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.